Form 4: LAVA Therapeutics Director Acquires Options in Latest Filing
SEC Form 4 Filing
Director Jay T. Backstrom acquires options to purchase 33,390 common shares of LAVA Therapeutics NV at $0.93 per share.
Summary
- On February 13, 2025, Jay T. Backstrom, a director of LAVA Therapeutics N.V., acquired options to purchase 33,390 common shares.
- The exercise price of the options is $0.93 per share.
- The options vest on February 13, 2026, contingent upon continued service with the Issuer or its subsidiary.
- The expiration date for the options is February 12, 2035.
- Following the transaction, Backstrom directly owns 33,390 common shares.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it simply reports an insider transaction. It doesn't inherently indicate positive or negative prospects for the company.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests between management and shareholders.
Stakeholder Impact
- The acquisition of options by a director can signal confidence in the company's future prospects, potentially impacting shareholder sentiment positively.
Key Dates
| Date | Description |
|---|---|
| 02/13/2025 | Date of earliest transaction: Director acquired options to purchase common shares. |
| 02/13/2026 | Vesting date for the options, contingent upon continued service. |
| 02/12/2035 | Expiration date of the options. |
| 02/18/2025 | Date of signature for the Form 4 filing. |
Keywords
LAVA Therapeutics, Director, Options, Acquisition, Common Shares, Form 4, Beneficial Ownership, LVTX
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.